Vicore builds case for C21 drug in hospitalised COVID-19 patientsTwo weeks ago, Vicore reported mid-stage data showing that its lead drug C21 could boost the benefit of Share XVicore builds case for C21 drug in hospitalised COVID-19 patientshttps://pharmaphorum.com/news/vicore-builds-case-for-c21-drug-in-hospitalised-covid-19-patients/
Phase 3 wins put Dermavant closer to filing Otezla rival tapinarofJust two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could Share XPhase 3 wins put Dermavant closer to filing Otezla rival tapinarofhttps://pharmaphorum.com/news/phase-3-wins-put-dermavant-closer-to-filing-otezla-rival-tapinarof/
Sanofi’s Dupixent backed for nasal polyps use in EuropeSanofi and Regeneron’s fast-growing immunology drug Dupixent is on course for a third indication in Europe after being Share XSanofi’s Dupixent backed for nasal polyps use in Europehttps://pharmaphorum.com/news/sanofis-dupixent-backed-for-nasal-polyps-use-in-europe/
Next gen psoriasis drugs show superiority to StelaraGuselkumab can also be used if older drug Stellara fails. Share XNext gen psoriasis drugs show superiority to Stelarahttps://pharmaphorum.com/news/janssen-guselkumab/